Please login to the form below

Not currently logged in
Email:
Password:

TNF

This page shows the latest TNF news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

TNF inhibitor Remicade’s sales fell by around 15% in the first nine months of the year to $4.1bn, mainly due to price reductions, while Tremfya sales were $369m globally

Latest news

More from news
Approximately 1 fully matching, plus 177 partially matching documents found.

Latest Intelligence

  • Customer experience rules the digital age Customer experience rules the digital age

    Take the area of anti-TNFs and their biosimilar competitors. Competition here is becoming fierce and is being led more and more by customers’ overall experiences, including service-led patient support

  • Deal Watch December 2016 Deal Watch December 2016

    Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not disclosed. Spherical Nucleic Acid technology and a topical anti-TNF product.

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Among these are Avaxia Biologics, which is developing an anti-tumour necrosis factor (TNF) antibody for inflammatory bowel disease and UK-based VH Squared, which has an early-stage programme ongoing

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    Versions of biologics have been on the market in Europe for a number of years now, but Remicade is the world's second-best selling medicine, and its fellow anti-TNF ... The two infliximab biosimilars are also included in the cost-effectiveness watchdog's

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics